期刊名称：CELL DEATH DISCOVERY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Aims and Scope
Cell Death Discovery is a multidisciplinary, international, online-only, open access journal, dedicated to publishing research at the intersection of medicine with biochemistry, pharmacology, immunology, cell biology and cell death, provided it is scientifically sound. The unrestricted access to research findings in Cell Death Discovery will foster a dynamic and highly productive dialogue between basic scientists and clinicians, as well as researchers in industry with a focus on cancer, neurobiology and inflammation research. As an official journal of the Cell Death Differentiation Association (ADMC), Cell Death Discovery will build upon the success of Cell Death & Differentiation and Cell Death & Disease in publishing important peer-reviewed original research, timely reviews and editorial commentary.
Cell Death Discovery is committed to increasing the reproducibility of research. To this end, in conjunction with its sister journals Cell Death & Differentiation and Cell Death & Disease, Cell Death Discovery provides a unique forum for scientists as well as clinicians and members of the pharmaceutical and biotechnical industry. It is committed to the rapid publication of high quality original papers that relate to these subjects, together with topical, usually solicited, reviews, editorial correspondence and occasional commentaries on controversial and scientifically informative issues.
Abstracting and indexing
Cell Death Discovery has been accepted into PubMed Central, and content is now visible on that site. As with any new journal, however, full indexing takes some time. Pending review and acceptance, all past published articles will be indexed retrospectively.
Cell Death Discovery articles also appear in Google Scholar.
Instructions to Authors
To find out about how to submit an article to Cell Death Discovery, please read the journal’s Instructions for Authors.
Once you have read the journal's Instructions for Authors, please submit your manuscript to the Cell Death Discovery manuscript tracking system. Springer Nature has introduced improvements to the manuscript tracking system used on many of our journals, designed to streamline your accounts with Springer Nature journals and conveniently provide you with more information in one place.
Editorial Board
Editors-in-Chief
Xin Lu
 UK, Oxford - Professor Xin Lu studied Biochemistry at Sichuan University and then Cancer Research at Peking Union Medical School in Beijing. She was awarded an IARC WHO fellowship to come to the Imperial Cancer Research Fund in London in 1986 and studied for her PhD under Birgit Lane. In 1993 she joined the Ludwig Institute for Cancer Research (LICR), St. Mary's Branch, Imperial College as an Assistant Member and was progressively promoted to LICR Full Member and Professor at Imperial College in 2000. In 2004, she was appointed as the Director of the LICR’s UCL Branch but moved the unit to Oxford in 2007. She is an elected Member of EMBO and Fellow of the Academy of Medical Sciences. Professor Lu's research is focused on understanding tumour suppression and to identify molecular switches that selectively kill cancer cells. Cancer is a disease where cells grow in the wrong place at the wrong time. Regenerative medicine involves growing cells to replace the ones that were lost or damaged. Therefore, understanding molecular mechanisms that control cell growth is vital, both to stop cancer cell growth and to grow normal cells to replace the damaged ones. Professor Lu's research team has been one of the major research groups in the world to study the regulation of the tumour suppressor function of the p53 protein whose function is lost in most human cancers. The majority of nuclear import pathways are mediated by importin-cargo interactions. Yet around 50% of all nuclear proteins do not use this pathway. Through a detailed understanding of the regulation of the ASPP proteins, Professor Lu's group has identified a code that defines RaDAR as a novel nuclear import pathway of ankyrin repeats (AR) containing proteins. AR is a structural motif found in over 250 human proteins with diverse functions. The RaDAR (RanGDP/AR) pathway is acquired by the most common familial melanoma associated CDKN2A mutation, leading to nuclear accumulation of mutant p16ink4a. It is frequently used by AR-containing transcriptional regulators, especially those regulating NF-ĸB/p53. All these suggest the existence of an Ankyrin repeats signaling and its role in infection and cancer.
KEYWORDS: apoptosis, p53, EBV, ASPP proteins, Ankyrin repeats signaling
Ivano Amelio
Italy, Rome and UK, Nottingham - Ivano Amelio is currently an AIRC Start-Up Group Leader at the TOR Centre of Excellence of the University of Rome “Tor Vergata” (Italy) and an Assistant Professor in the School of Life Sciences at the University of Nottingham (UK). His work aims to understand the molecular basis of tumour suppression signalling with a particular focus on the role of p53 family members, microenvironmental hypoxia and metabolic alterations.
His training started at the University of Rome Tor Vergata (Italy) where in 2011 he received the PhD in Biochemistry and Molecular Biology, elucidating a novel microRNA-mediated mechanism regulating the balance of epidermal cell proliferation/differentiation. His research activity then continued at the MRC Toxicology Unit, University of Cambridge (UK), where in 2016 he received the appointment of Senior Investigator Scientist. His major contributions include the identification of specific functions for p53 family members in cellular stress response, mediated by p73 regulation of cancer metabolism, angiogenesis, and development. More recently, he revealed a novel gain-of-function effect of p53 mutants in hypoxic tumours.
Ivano is a member of the board of directors of the European Cell Death Organisation (ECDO) and member of a number of international advisory boards. He has served as Editor-in-Chief of Cell Death Discovery since 2018 and as member of the editorial board of Cell Death & Disease and Molecular and Cellular Oncology since 2017 and 2014 respectively.
KEYWORDS: p53, DNA damage response, hypoxia, miR, skin biology
The Cell Death Discovery international Editorial Board spans the breadth of the coverage of the journal – view the full Editorial Board.
|
